Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this morning that it has added $10 million in convertible note funding to its combination with NKGen Biotech.
NKGen’s majority shareholder NKMax (KOSDAQ:182400) has put up the cash for the move and in exchange the notes are to bear interest payable at either a 5% rate in cash or 8% in stock. They will mature in 2027 on the agreement’s fourth anniversary and can be exercised for 1,000,000 shares at $11.50 per share.
This new funding comes as Graf IV has postponed its completion vote with NKGen three times as it engages with shareholders and tries to hit its $50 million minimum cash condition.
Its shareholders are currently set to reconvene at 10 am ET, September 20 and it has until September 25 to complete a deal.
Graf IV went into this string of meetings with about $62.2 million in trust and NKMax had already committed to a backstop of up to $25 million. According to the filing, the SPAC plans to continue to seek out additional funds to bring the deal to a close.
The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.
At the SPAC of Dawn Lost in the daily assault of A.I. company news are all of the “other” companies that were created in the past decade or so. The normies. These venture-backed companies that achieved unicorn status during the boom years of 2020 and 2021 have been sidelined and much has been discussed about...
Quantum computing has been one of the hottest investment topics in the past two months and three of the leading listed companies in the space are de-SPACs. But, how close is quantum computing to generating real value and what capabilities are still years away? This week, we speak with Alan Baratz, CEO of D–Wave (NYSE:QBTS), which...
At the SPAC of Dawn The sudden burst of SPAC activity this week slowed down after the closing bell yesterday as the market faces a period sandwiched between CPI and PPI readouts. Yesterday’s CPI news and Fed Chair Jerome Powell’s comments before Congress did not provide an instant relief in terms of clarity on a...
Maywood Acquisition Corp. (NASDAQ:MAYAU) announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MAYAU”, Thursday, February 13, 2025. Maywood will have a broad search focus and will pursue an initial business combination in any industry or geographic location. The team is led...
Artius II Acquisition Inc. (NASDAQ:AACBU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “AACBU”, Thursday, February 13, 2025. Artius II intends to search for a target company with a technology-enabled business with opportunities that have multiple vectors to create value post-combination....